ADAP - Adaptimmune Therapeutics plc
| Previous Close | 1.6300 |
| Open | 1.6200 |
| Bid | 1.5700 x 1100 |
| Ask | 1.5800 x 900 |
| Day's Range | 1.5600 - 1.6600 |
| 52 Week Range | 1.4400 - 14.5400 |
| Volume | 136,047 |
| Avg. Volume | 286,923 |
| Market Cap | 166.101M |
| Beta (3Y Monthly) | 1.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9670 |
| Earnings Date | Mar 15, 2019 - Mar 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
- Zacks
What's in Store for Aytu BioScience's (AYTU) Q4 Earnings?
On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its diversified portfolio of medicines approved to treat ailments like low testosterone, insomnia and male infertility.
- Thomson Reuters StreetEvents
Edited Transcript of ADAP earnings conference call or presentation 1-Aug-19 12:00pm GMT
Q2 2019 Adaptimmune Therapeutics PLC Earnings Call
Motley FoolAdaptimmune Therapeutics (ADAP) Q2 2019 Earnings Call Transcript
ADAP earnings call for the period ending June 30, 2019.
- GlobeNewswire
New Executive Team Announced at Adaptimmune
Adaptimmune Therapeutics plc (ADAP), a leader in T-cell therapy to treat cancer, today announced changes to its Executive Team. In addition, the Company will report financial results for the Second Quarter 2019 and provide a business update today at 8:00 a.m. EDT (1:00 p.m. BST) with details for the accompanying live teleconference and webcast provided below.
- GlobeNewswire
Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update
- Started SPEARHEAD-1 clinical trial with ADP-A2M4 in synovial sarcoma and MRCLS patients – - Started low-dose radiation sub-study with ADP-A2M4 with the MD Anderson Cancer.
- GlobeNewswire
Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019
PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 29, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial.
- GlobeNewswire
Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS
- Compelling data reported with ADP-A2M4 SPEAR T-cells in synovial sarcoma - - Adaptimmune plans to launch a TCR T-cell therapy in 2022 - PHILADELPHIA and OXFORDSHIRE, United.
- GlobeNewswire
Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center
- Compelling responses previously reported with ADP-A2M4 in sarcoma - - Use of low-dose radiation intended to enhance antitumor activity - PHILADELPHIA and OXFORDSHIRE, United.
- Simply Wall St.
How Should Investors Feel About Adaptimmune Therapeutics plc's (NASDAQ:ADAP) CEO Pay?
In 2014 James Noble was appointed CEO of Adaptimmune Therapeutics plc (NASDAQ:ADAP). This report will, first, examine...
- GlobeNewswire
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor Responses
Adaptimmune Therapeutics plc, Philadelphia, PA, and Oxfordshire, UK (ADAP), a leader in T-cell therapy to treat cancer, has initiated SURPASS, its first clinical trial with a next-generation SPEAR T-cell targeting MAGE-A4. This next-generation SPEAR T-cell, known as ADP‑A2M4CD8, expresses the CD8α co-receptor alongside the engineered TCR that targets MAGE-A4. Preclinical data presented earlier this year at AACR indicate that co-expression of CD8α may broaden the immune response against solid tumors and increase antitumor activity by leveraging CD4+ cells into CD8+ killer or cytotoxic T‑cells while retaining their CD4+ helper function.
- Zacks
Athenex (ATNX) in Focus: Stock Moves 6.5% Higher
Athenex (ATNX) shares rose nearly 7% in the last trading session, amid huge volumes.
- Zacks
Adaptimmune Therapeutics PLC (ADAP) Upgraded to Strong Buy: Here's Why
Adaptimmune Therapeutics PLC (ADAP) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Insider Monkey
Is Adaptimmune Therapeutics plc (ADAP) Going to Burn These Hedge Funds?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
- Insider Monkey
Hedge Funds Piled Into This Stock Right Before Its 40% Ascend
We at Insider Monkey have gone over 738 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st. In this article, we look at what those funds think of Control4 Corp (NASDAQ:CTRL) based on that data. […]
- GlobeNewswire
Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer
Adaptimmune Therapeutics plc (ADAP) today announced that Adrian Rawcliffe, currently Chief Financial Officer (CFO) of the Company, will succeed James Noble as Chief Executive Officer (CEO). This transition will occur when James retires from his executive duties and transitions to a non-executive director role on the Company’s Board on September 1, 2019.
- Simply Wall St.
Those Who Purchased Adaptimmune Therapeutics (NASDAQ:ADAP) Shares A Year Ago Have A 72% Loss To Show For It
As every investor would know, you don't hit a homerun every time you swing. But serious investors should think long...
- American City Business Journals
AdaptImmune partners to advance promising cancer immunotherapies
Alpine gets $2 million from Adaptimmune now, and up to $290 million if the partnership is successful in producing next-generation cancer immunotherapies.
- GlobeNewswire
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
Adaptimmune Therapeutics plc (ADAP), a leader in T-cell therapy to treat cancer, and Alpine Immune Sciences, Inc., Seattle, WA, (ALPN), a leading immunotherapy company focused on developing treatments for autoimmune diseases and cancer, today announced a collaboration and license agreement to develop next-generation SPEAR T-cell products which incorporate Alpine’s secreted and transmembrane immunomodulatory protein (termed SIP™ and TIP™) technology. This collaboration will further enhance Adaptimmune’s efforts to design and develop next-generation SPEAR T-cell therapies. “SPEAR T-cell therapies have demonstrated clinical promise for the treatment of solid tumors.
- GlobeNewswire
Adaptimmune Reports First Quarter 2019 Financial Results
- Clinical update issued in a separate announcement - - Financial guidance updated: funded into Q3 2020 - PHILADELPHIA and OXFORD, United Kingdom, May 06, 2019 -- Adaptimmune.
- GlobeNewswire
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
- Partial responses in 4 out of 5 synovial sarcoma patients treated with ~10 billion cells, with tumor shrinkage in nearly all assessed synovial sarcoma patients in the ADP-A2M4.
- GlobeNewswire
Adaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT Meeting
- Data show strong progress with off-the-shelf program demonstrating T-cell differentiation from stem cells (hiPSC) in a serum-free process without the addition of mouse stromal.
- GlobeNewswire
Adaptimmune to Provide Clinical and Business Update on Monday May 6th, 2019
PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 01, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will provide a clinical.
- GlobeNewswire
Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting
- Presentation to include overview of substantial progress of Adaptimmune’s off-the-shelf SPEAR T-cell platform - - Data will show that hiPSC-derived allogeneic SPEAR T-cells.
GuruFocus.comThese 3 Falling Knives Are Expected to Outperform
Further, these companies have a GuruFocus financial strength rating of at least 5 out of 10, reducing the bankruptcy rate risk, which is quite common among falling knives. Warning! GuruFocus has detected 2 Warning Signs with NKTR. The closing price on Thursday was 22.5% off the 52-week low of $29.22 and 193% from the 52-week high of $104.88.
- GlobeNewswire
Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting
PHILADELPHIA and OXFORD, United Kingdom, April 02, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial safety.
